Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Ardx save search
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
Published: 2023-11-15 (Crawled : 21:00) - globenewswire.com
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 0.78%
H: 3.72%
C: 3.33%
xphozah fda drug granted treatment designation hyperphosphatemia
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
Published: 2023-10-17 (Crawled : 23:00) - globenewswire.com
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 13.62%
H: 5.1%
C: -0.26%
xphozah fda
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)User Fee Goal Date: October 17, 2023
Published: 2023-05-17 (Crawled : 12:20) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: -6.5%
H: 1.11%
C: -5.76%
xphozah fda drug resubmission review application
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
Published: 2023-05-17 (Crawled : 11:00) - globenewswire.com
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: -6.5%
H: 1.11%
C: -5.76%
xphozah fda drug resubmission review application
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
Published: 2022-12-29 (Crawled : 12:20) - prnewswire.com
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: -0.4%
H: 6.8%
C: 1.2%
xphozah fda grants
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Published: 2022-11-16 (Crawled : 00:00) - prnewswire.com
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 61.48%
H: 0.51%
C: -12.69%
xphozah fda disease kidney control benefits dialysis
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Published: 2022-11-16 (Crawled : 15:00) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
| Email alert
Add to watchlist
xphozah fda disease kidney control dialysis
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
Published: 2022-04-25 (Crawled : 12:00) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 39.02%
H: 4.85%
C: -4.28%
xphozah fda tenapanor
Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug
Published: 2021-11-05 (Crawled : 17:00) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 5.24%
H: 1.15%
C: -8.05%
fda drug
Ardelyx Provides Corporate Update Following Type A Meeting with FDA
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: -18.18%
H: 6.48%
C: 0.93%
fda
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
ARDX | News | $6.445 -1.6% -1.63% 3.5M
|
Health Technology
|
| O: 0.58%
H: 2.3%
C: -1.72%
new drug fda drug tenapanor dialysis
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.